Louisiana § 40:1081.1 Programs for combating phenylketonuria, congenital hypothyroidism,

Louisiana Statutes

§ 40:1081.1 — Programs for combating phenylketonuria, congenital hypothyroidism,

Louisiana § 40:1081.1

Title 40Public Health and Safety

This text of Louisiana § 40:1081.1 (Programs for combating phenylketonuria, congenital hypothyroidism,) is published on Counsel Stack Legal Research, covering Louisiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

La. Stat. Ann. § 40:1081.1 (2026).

Text

§1081.1. Programs for combating phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, biotinidase deficiency, and other genetic conditions A. The Louisiana Department of Health is hereby authorized and directed to establish, maintain, and carry out programs designed to reduce mortality and morbidity from sickle cell disease and to prevent central nervous system damage in children with phenylketonuria, congenital hypothyroidism, biotinidase deficiency, galactosemia and genetic conditions tested under the authority of R.S. 40:1081.2(B). B.

(1)The Louisiana Department of Health shall establish and maintain a diagnostic laboratory for each of the following purposes:

(a)Conducting experiments, projects, and other undertakings as may be necessary to develop tests for t

Free access — add to your briefcase to read the full text and ask questions with AI

§1081.1. Programs for combating phenylketonuria, congenital hypothyroidism,
galactosemia, sickle cell diseases, biotinidase deficiency, and other genetic conditions
A. The Louisiana Department of Health is hereby authorized and directed to
establish, maintain, and carry out programs designed to reduce mortality and morbidity from
sickle cell disease and to prevent central nervous system damage in children with
phenylketonuria, congenital hypothyroidism, biotinidase deficiency, galactosemia and
genetic conditions tested under the authority of R.S. 40:1081.2(B).
B.(1) The Louisiana Department of Health shall establish and maintain a diagnostic
laboratory for each of the following purposes:
(a) Conducting experiments, projects, and other undertakings as may be necessary
to develop tests for the early detection of phenylketonuria, congenital hypothyroidism,
galactosemia, sickle cell diseases, biotinidase deficiency, and other genetic conditions.
(b) Developing ways or discovering methods to be used for the prevention and
treatment of these diseases.
(c) Such other purposes as may be deemed necessary by the department to carry out
any program adopted under the authority of this Subpart, including conducting experiments,
projects, and other undertakings as may be necessary to develop tests for genetic conditions
made part of the battery of tests by the Louisiana Department of Health under R.S.
40:1081.2(B).
(2) Notwithstanding the foregoing, the term "prevention" as used with respect to
sickle cell anemia shall not mean mandatory sterilization or abortion.
C. The department is authorized to adopt rules and regulations necessary to carry out
any program which may be established.
D. The Louisiana Department of Health shall establish a program for informing
physicians and hospitals of the current medical standards for diagnosing and treating children
who exhibit clinical symptoms which suggest the existence of galactosemia. This program
shall be established in consultation with and shall be based on the recommendations of the
Louisiana Hospital Association and the Louisiana State Medical Society.

Legislative History

Acts 1964, No. 269, §1. Amended by Acts 1978, No. 442, §2; Acts 1978, No. 786, §5, eff. July 17, 1978; Acts 1981, No. 430, §1; Acts 1982, No. 375, §1; Acts 1984, No. 265, §2; Acts 1987, No. 598, §1, eff. July 9, 1987; Acts 1989, No. 91, §1; Acts 1991, No. 729, §1; Acts 1993, No. 997, §1; Acts 1999, No. 328, §1; Redesignated from R.S. 40:1299 by HCR 84 of 2015 R.S.